drug pricing regulation
Government and payer limits on drug prices, such as Medicare price negotiation under the IRA.
Exposure · 25 companies
ABBV AbbVie
Exposed“Pricing and reimbursement pressure in the U.S. and internationally could reduce revenue and earnings.”
- Revenue$61.2BYoY +8.6%
- Net income$4.2BYoY −1.2%
- Revenue$17.4BYoY +10.3%
- Net income$4.2Bvs $186.0M year ago
AMGN Amgen
Exposed“CMS has set Medicare Part D prices for ENBREL, effective January 1, 2026, and Otezla, effective January 1, 2027, in each case at significantly lower prices that are expected to negatively impact their profitability in Medicare.”
- Revenue$36.8BYoY +10.0%
- Net income$7.7BYoY +88.5%
- Revenue$10.4BYoY +8.5%
- Net income$3.9BYoY +20.1%
APMD Apnimed, Inc.
Exposed“Third-party payors, however, are increasingly challenging pharmaceutical prices and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.”
ASPE Aspen Neuroscience, Inc.
Exposed“Adoption or expansion of price controls and cost-containment measures could further limit our net revenue and results.”
ATTO Attovia Therapeutics, Inc.
Exposed“U.S. pricing risks include Medicare negotiation and inflation rebates under the IRA, ACA-related changes, and other federal and state drug-pricing initiatives; the filing also flags OBBBA-related changes and announced Most-Favored-Nation pricing initiatives.”
BLSM BlossomHill Therapeutics, Inc.
Exposed“Pricing pressure, payor restrictions, and changes to U.S. drug-pricing and healthcare policies could further constrain commercial returns.”
BMY Bristol-Myers Squibb
Exposed“BMS faces intensifying pricing, reimbursement and market-access pressure in the U.S. and internationally, with potential effects on revenue and margins.”
- Revenue$48.2BYoY −0.2%
- Net income$7.1Bvs −$8.9B year ago
- Revenue$13.1BYoY +6.9%
- Net income$2.2BYoY −1.8%
BRVE Braveheart Bio, Inc.
Exposed“The Trump Administration has issued executive orders and supported proposed regulatory initiatives in 2025 that could have a significant impact on the prices that we, or any collaborators, may receive for any approved products.”
CI Cigna Group
Exposed“These initiatives include contract renewals, investment in a rebate-free model and recontracting around affordability and government programs, including the Inflation Reduction Act.”
- Revenue$73.7BYoY +5.6%
- Net income$1.4BYoY −22.8%
CVS CVS Health
Exposed“Pharmacy & Consumer Wellness: Q3 revenue and operating income reflected regulatory-related drug price reductions, generic introductions and reimbursement pressure, partly offset by favorable drug mix, brand inflation, prescription volume and Rite Aid contributions.”
- Revenue$108.4BYoY +5.4%
- Net income$2.2Bvs −$4.0B year ago
ELV Elevance Health
Exposed“Other exposures include PBM legislation affecting rebates, reporting and Medicare Part D compensation; No Surprises Act disputes; mental-health-parity requirements; litigation and government reviews; cyber, privacy, technology and data-integrity risks; competition; and potential goodwill or intangible-asset impairment.”
- Revenue$51.4BYoY +1.4%
- Net income$1.4BYoY +14.8%
ETRA Electra Therapeutics, Inc.
Exposed“U.S. drug-pricing and healthcare reforms, Medicare negotiation and rebates, and foreign price controls, reimbursement reviews, and health technology assessments could reduce access or commercial returns.”
GILD Gilead Sciences
Exposed“Gilead expects IRA provisions to increase payment and rebate obligations and affect prices and profitability, potentially extending to other payer segments.”
- Revenue$8.3BYoY +6.8%
- Net income$2.4BYoY −20.4%
INVA Innoviva, Inc.
Exposed“The Inflation Reduction Act adds direct exposure: RELVAR/BREO’s negotiated Medicare maximum fair price is scheduled to take effect **January 1, 2027**, and ANORO’s negotiated pricing is expected to take effect in **2028**.”
- Revenue$411.3MYoY +14.7%
- Net income$271.2Mvs $23.4M year ago
- Revenue$106.1MYoY −1.6%
- Net income−$73.9Mvs $89.9M year ago
JNJ Johnson & Johnson
Exposed“The federal Inflation Reduction Act of 2022 (IRA) includes provisions that effectively authorize the government to establish prices for certain high-spend single-source drugs and biologics reimbursed by the Medicare program, starting in 2026 for Medicare Part D drugs and 2028 for Medicare Part B drugs.”
- Revenue$94.2BYoY +6.0%
- Net income$26.8BYoY +90.6%
- Revenue$25.4BYoY +5.9%
- Net income$210.0MYoY −95.9%
LLY Eli Lilly and Company
Exposed“Restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private actors have and may continue to adversely impact our business and financial results.”
- Revenue$65.2BYoY +44.7%
- Net income$20.6BYoY +94.9%
- Revenue$24.4BYoY +38.6%
- Net income$6.5BYoY +15.5%
MCK McKesson Corporation
Exposed“The business also remains exposed to evolving drug-pricing policy, the federal 340B program and government healthcare funding.”
- Revenue$111.0BYoY +7.6%
- Net income$1.2BYoY +9.7%
MRK Merck & Co.
Exposed“The IRA also increases manufacturer liability under Medicare Part D from 2025, applies inflation-based penalties, and enables government price setting for Medicare drugs.”
- Revenue$65.0BYoY +1.3%
- Net income$18.3BYoY +6.6%
- Revenue$18.1BYoY +4.7%
- Net income$5.1BYoY −12.4%
PFE Pfizer
Exposed“Any significant efforts at the federal or state levels to reform the healthcare system by changing the way healthcare is provided or funded or to expand controls on drug pricing, implement international reference pricing, including Most-Favored-Nation (MFN) drug pricing, or impact government reimbursement and access to medicines and vaccines on public and private insurance plans or consumer purchasing platforms could have a material impact on us.”
- Revenue$62.6BYoY −1.6%
- Net income$7.8BYoY −3.2%
- Revenue$16.6BYoY −0.4%
- Net income$3.2BYoY −8.4%
REGN Regeneron Pharmaceuticals
Exposed“The agreements are expected to reduce prices and reimbursement for certain products; in return, qualifying products are not expected to face Section 232 tariffs through January 2029, subject to conditions that include continued U.S. manufacturing and R&D investment.”
- Revenue$5.1BYoY +36.3%
- Net income$1.9BYoY +33.5%
RZRA Rezera Inc.
Exposed“Prescription drug pricing in the U.S. is subject to significant political, legislative, and regulatory scrutiny.”
SCTX Scribe Therapeutics, Inc.
Exposed“Healthcare pricing policies, including Medicare negotiation and potential most-favored-nation pricing, could pressure future prices and market opportunity.”
SDGR Schrödinger, Inc.
Exposed“Medicare drug-price negotiation is expanding under the IRA, alongside inflation rebates and other pricing measures; federal, state, and international reimbursement controls may limit prices or access.”
- Revenue$255.9MYoY +23.3%
- Net income−$103.3MYoY +44.8%
- Revenue$64.5MYoY +18.7%
- Net income−$37.7MYoY −15.0%
VOGX Vogenx, Inc.
Exposed“Drug-price controls, including IRA negotiation and rebate provisions, evolving federal actions, and foreign price restrictions could limit future pricing and profitability.”
WWB WINDWARD BIO GROUP AG
Exposed“Evolving U.S. and EU drug-pricing, reimbursement, and health-technology-assessment policies add uncertainty.”
No companies have a recent 8-K matching these events.
No companies in the selected roles.